02/25/2013
https://www.congress.gov...
"HHS and FDA need to step up their oversight efforts in this area."
"The GAO found that an emphasis on profits can lead private equity backed IRBs to rubber stamp reviews of drug clinical trials."
"According to a recent GAO report, despite representing just two percent of the review boards, these commercial IRBs now review over half of studies involving investigational new drugs."
"I want to say again thank you to Senator Braun for holding this hearing."